Tests a digital app and home scale in children with obesity
Tests a digital app and home scale added to usual care for children with obesity.
Plain-language title generated from the registry record
Registry title: A Multicenter Study for Evaluating a Digital Support System in Childhood Obesity Treatment
Key facts
- Where
- Szczecin, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 17 years old?
Source: NCT04917601, who can take part
Where in Poland
- Samodzielny Publiczny Szpital KlinicznySzczecin, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska Institutet
- Trial code
- NCT04917601
- Record updated
- 6 October 2025
- Original description
Evira is a digital support system newly developed for treatment of childhood obesity. Through daily weighings at home using a special scale together with a message function in the Evira application, enabling fast and easy communication with the clinic, parents and the clinicians can easily follow the child's weight development. The purpose of this randomized controlled study is to evaluate the effect of adding Evira to the already locally used life-style treatment of childhood obesity.Read full original descriptionShow less
A Randomized Controlled Multicenter Study for Evaluating a Digital Support System in Childhood Obesity Treatment (EurEvira)
Evira is a digital support system newly developed for treatment of childhood obesity. Through daily weighings at home using a special scale together with a message function in the Evira application, enabling fast and easy communication with the clinic, parents and the clinicians can easily follow the child's weight development. The purpose of this randomized controlled study is to evaluate the effect of adding Evira to the already locally used life-style treatment of childhood obesity.
Inclusion: Age >4.0 and <17.0 years of age at inclusion; Obesity defined based on the International Obesity Task Force criteria iso-BMI 30 - 40 kg/m2; Willingness to participate in an obesity treatment clinical trial; Family ability to communicate in the language of the country of residence e.g. write and read messages in the mobile application; Parents having a smart phone and an email address.
Exclusion: Treatment for depression and other psychiatric disorders during the last 6 months before inclusion; Eating disorders requiring therapy during the last six months before inclusion or observed at the inclusion screening; Endocrine disorders other than well controlled hypothyroidism; Metabolic disorders of importance for weight control - to be discussed; Hypothalamic or monogenic obesity, e.g. syndromes and Mb Down; Severe neuropsychiatric disorders that could affect study compliance; Morbid obesity defined as iso-BMI>40kg/m2 independently of age; Pharmacological treatment of importance for weight control.